Daily Cosmetic Research Analysis
Analyzed 3 papers and selected 3 impactful papers.
Summary
Analyzed 3 papers and selected 3 impactful articles.
Selected Articles
1. Comparative study of interstitial brachytherapy and intensity-modulated radiotherapy as tumour bed boost after conservative surgery for breast cancer: Toxicity and cosmetic outcomes.
Prospective study of 60 patients after breast-conserving surgery compared interstitial brachytherapy boost (n=30) with external beam boost (n=30). Cosmetic outcomes were comparable (excellent/good in 85%), but late skin toxicity and doses to heart/skin were significantly lower with interstitial brachytherapy.
Impact: Directly informs choice of tumour-bed boost modality after breast-conserving surgery by demonstrating equivalent cosmesis but lower late skin toxicity and organ doses with interstitial brachytherapy in a prospective cohort.
Clinical Implications: Supports consideration of interstitial brachytherapy as the preferred boost option in suitable patients to reduce late skin toxicity and normal-structure dose, while expecting comparable cosmetic outcomes; informs shared decision-making between radiotherapy modalities.
Key Findings
- Excellent/good cosmetic outcome observed in 85% of patients overall, with no significant difference between brachytherapy and external beam boost.
- Late skin toxicity was significantly lower in the interstitial brachytherapy group.
- Doses to normal structures (heart and skin) were significantly lower with brachytherapy; factors associated with worse cosmesis included central tumour location, neoadjuvant chemotherapy, >2 cm vertical nipple deviation, and grade 3 skin induration.
Methodological Strengths
- Prospective enrollment with predefined treatment protocols for boost modalities.
- Median follow-up of 56 months provides meaningful assessment of late toxicity and cosmetic outcomes.
Limitations
- Non-randomized design with potential selection bias between boost modalities.
- Relatively small sample size (n=60) limits subgroup analyses and external generalizability.
Future Directions: A randomized trial or larger multicenter prospective cohort could confirm these findings and define patient subgroups most likely to benefit from brachytherapy boost.
INTRODUCTION: Radiotherapy improves survival of patients who underwent breast-conserving surgery. Tumour bed boost further improves the local control that can be delivered by interstitial brachytherapy, electron beam or X-ray photon beam therapy (external beam radiotherapy). The aim of the study was to compare cosmetic outcome and the factors affecting it after interstitial brachytherapy or external beam radiotherapy. MATERIALS AND METHODS: Sixty patients with infiltrating ductal carcinoma who underwent breast conserving surgery were prospectively enrolled and treated by electron or X-ray photon beams to a total dose of 40Gy delivered in 15 fractions followed by tumour bed boost by interstitial brachytherapy (n=30) or external beam radiotherapy (n=30) to a dose of 14Gy delivered in four fractions. Both the groups were compared in terms of cosmesis, acute toxicity, late toxicity, dosimetry and survival. RESULTS: Median follow up period of the cohort was 56 months (range: 50-63months). There was no significant difference in the two groups in terms of toxicity and cosmetic outcome. Excellent/good cosmesis was seen in 85 % of total patients. Late skin toxicity was significantly lower in the group receiving interstitial brachytherapy. Doses to the normal structures such as heart and skin were significantly lower in patients who had brachytherapy. Using univariate analysis, tumour location (central region), use of neoadjuvant chemotherapy, vertical nipple deviation of more than 2cm and grade 3 skin induration were found to be significantly associated with fair/poor cosmetic outcome. CONCLUSION: Tumour bed boost by external beam radiotherapy or interstitial brachytherapy provide equivalent result in terms of cosmesis. Interstitial brachytherapy has an edge over external beam radiotherapy in reducing skin doses resulting in decreased incidence of higher grade of late skin toxicity.
2. Sargassum latifolium-mediated Se/CuO/MgO/ZnO nanocomposite enhances salt tolerance in Phaseolus vulgaris and exhibits antibacterial and antioxidant activities.
Authors report green biosynthesis of a Se/CuO/MgO/ZnO tetrametallic nanocomposite using Sargassum latifolium. Characterized as ~24 nm polycrystalline spheres, foliar application (50–200 ppm) improved salt-stress tolerance in Phaseolus vulgaris (notably at 200 ppm) with increases in photosynthetic pigments, osmolytes, and yield-related metabolites; the material also showed potent antibacterial and antioxidant activities.
Impact: Introduces a novel, algae-mediated multimetallic nanocomposite with dual agronomic (salt-tolerance) and antimicrobial/antioxidant properties that may enable sustainable crop stress mitigation and pathogen control.
Clinical Implications: Not directly clinical; implications are primarily in agricultural biotechnology and antimicrobial material development. Potential downstream translational relevance includes crop yield stabilization under salinity and novel antimicrobial agents, which could indirectly affect food security and infectious disease control.
Key Findings
- Successful green synthesis of Se/CuO/MgO/ZnO tetrametallic nanocomposite using Sargassum latifolium with average particle size ~24 nm confirmed by TEM/EDX/XRD.
- Foliar application of TSCMZ (50–200 ppm; best effect at 200 ppm) mitigated 100 mM NaCl-induced growth and metabolic impairments in Phaseolus vulgaris, increasing chlorophylls, carotenoids, free proline, carbohydrates, and proteins.
- TSCMZ exhibited potent antibacterial activity with low MIC values (reported 12.5–25 µg/mL) and notable antioxidant properties.
Methodological Strengths
- Comprehensive material characterization (FT-IR, TEM, SAED, EDX, XRD) supporting structural claims.
- Field-condition testing on Phaseolus vulgaris with dose–response (50–200 ppm) and multiple biochemical endpoints measured.
Limitations
- Sample sizes and detailed experimental replicates in field trials are not specified in the abstract, limiting assessment of statistical robustness.
- Potential environmental/toxicity impacts of multimetal nanocomposite (soil accumulation, non-target organisms) were not addressed.
Future Directions: Further work should report detailed sample sizes/statistics, evaluate environmental and non-target toxicity, test across crop species and salinity gradients, and study mechanisms of action at molecular level.
Macroalgae represents a powerful, renewable bioplatform for generating high-performance nanomaterials that bridge sustainability with advanced biotechnological applications. However, crop production and multi-drug resistance microbes are considered the main challenge worldwide. Also, the incorporation of macroalgae metabolites to generate multimetallic nanocomposite, as a new active compound, remains unexplored. In this work, the brown macroalga Sargassum latifolium was exploited as a robust biofactory for the green fabrication of multifunctional active tetrametallic Se/CuO/MgO/ZnO (TSCMZ) nanocomposite. The biosynthesized TSCMZ were characterized by FT-IR which explains the role of different algal-active metabolites in biofabrication process. Also, TEM, SAED, and EDX confirm the spherical shape with average sizes of 24 nm and the presence of metallic elements as main nanocomposite component. Polycrystalline architecture of synthesized nanocomposite was confirmed by XRD analysis. Under field conditions, Phaseolus vulgaris L. exposed to 100 mM NaCl experienced drastic impairments in growth, metabolism, and yield stability. Remarkably, foliar application of TSCMZ (50-200 ppm), especially at 200 ppm, significantly mitigate salt stress, elevating metabolic performance, and recovering key yield attributes. This enhancement was accompanied by substantial increases in chlorophylls (a, b, and a + b), carotenoids, free proline, carbohydrate and protein biosynthesis, indicating strengthened osmotic adjustment and redox homeostasis. Beyond its agronomic impact, TSCMZ displayed striking antibacterial potency, with low MIC values (12.5-25 µg mL
3. Preparation of fucose-containing galacto-oligosaccharides using a commercial β-galactosidase from Bifidobacterium bifidum.
The authors optimized conditions using a commercial β-galactosidase (Nurica) to synthesize fucose-containing galacto-oligosaccharides, identifying structures from di- to hexasaccharides. Fucose was mainly at the reducing end and substituted predominantly at C3; multiple linkage types (including 1,2/1,3/1,4/1,6 β-glycosidic bonds) were characterized.
Impact: Provides a practical enzymatic route to generate fucosylated galacto-oligosaccharides that mimic human milk oligosaccharide features, potentially useful for infant formula supplementation and gut-microbiome modulation studies.
Clinical Implications: Translational potential for designing HMO-mimetic prebiotics for infant nutrition and microbiome-directed interventions; not immediately clinical but supports product development and mechanistic studies of gut colonization.
Key Findings
- Optimized reaction conditions with commercial β-galactosidase yielded a range of fucose-containing galacto-oligosaccharides from disaccharides to hexasaccharides.
- Fucose residues were predominantly located at the reducing end and mainly substituted at the C3 position, with less frequent 1,2- and 1,4-linkages.
- Multiple β-glycosidic linkages (1,2; 1,3; 1,4; 1,6) were identified between galactose and glucose units, including internal linkages in tri- and tetrasaccharides.
Methodological Strengths
- Use of a commercial enzyme increases reproducibility and translational potential for scale-up.
- Detailed structural characterization of products (linkage positions and chain lengths) supports mechanistic understanding.
Limitations
- Yield metrics and scalability details are not fully detailed in the abstract, limiting assessment of industrial feasibility.
- Biological activity (e.g., prebiotic effect, resistance to digestion, impact on infant gut microbiota) was not reported here.
Future Directions: Next steps should quantify yields/scalability, test resistance to gastrointestinal digestion, and evaluate biological effects on infant-relevant microbial strains or in vivo models.
Human milk fucose-containing oligosaccharides play a significant role in the development and function of the infant gastrointestinal tract. Fucosyltransferases catalyse the formation of these oligosaccharides. This work focuses on the preparation and characterisation of fucose-containing galacto-oligosaccharides using the commercial β-galactosidase Nurica. We optimised the reaction conditions to increase the yield of fucose-containing galacto-oligosaccharides. We detected a variety of structures containing fucose, ranging from disaccharides to hexasacharides. Fucose was located predominantly at the reducing end and, to a lesser extent, at the non-reducing end or within the chain. Like galactose, fucose was substituted mainly at the C3 position, although 1,2- and 1,4-linkages also occurred, albeit in a less pronounced manner. In addition, 1,2-, 1,3-, 1,4-, and 1,6-β-glycosidic linkages were identified between the galactose and glucose units, including internal units in tri- and tetrasaccharides.